<SEC-DOCUMENT>0001213900-25-121452.txt : 20251215
<SEC-HEADER>0001213900-25-121452.hdr.sgml : 20251215
<ACCEPTANCE-DATETIME>20251215073002
ACCESSION NUMBER:		0001213900-25-121452
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20251215
FILED AS OF DATE:		20251215
DATE AS OF CHANGE:		20251215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tiziana Life Sciences Ltd
		CENTRAL INDEX KEY:			0001723069
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38723
		FILM NUMBER:		251570020

	BUSINESS ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB
		BUSINESS PHONE:		0044(0) 207-495-2379

	MAIL ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tiziana Life Sciences plc
		DATE OF NAME CHANGE:	20171116
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0269677-6k_tiziana.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>FORM&nbsp;6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
2025</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number:</B>&nbsp; <B>001-38723</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Tiziana
Life Sciences LTD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>9<SUP>th</SUP>&nbsp;Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>107
Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>London
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>EC2V
6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of registrant&rsquo;s principal executive office)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;20-F&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form&nbsp;40-F&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
CONTAINED IN THIS REPORT ON FORM&nbsp;6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 15, 2025, Tiziana Life Sciences LTD (the &ldquo;<U>Company</U>&rdquo;) issued this 6K announcing, the withdrawal of the proposed
public offering of common shares due to market conditions.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Announcement is furnished herewith as Exhibit 99.1 to this Report on Form&nbsp;6-K. The information in the attached Exhibits 99.1 is
being furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section&nbsp;18 of the Securities Exchange Act of 1934,
or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company
under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall
be expressly set forth by specific reference in such a filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TIZIANA LIFE SCIENCES LTD</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: December 15, 2025</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Keeren Shah</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keeren Shah</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT&nbsp;INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 90%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&#9;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><A HREF="ea026967701ex99-1_tiziana.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tiziana Life Sciences LTD
    Press Release, dated December 15, 2025</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea026967701ex99-1_tiziana.htm
<DESCRIPTION>TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED DECEMBER 15, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tiziana Life Sciences Announces Withdrawal of
Proposed Public Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BOSTON, MA, December 15, 2025</B> &ndash; Tiziana Life Sciences,
Ltd. (Nasdaq: TLSA) (&ldquo;Tiziana&rdquo; or the &ldquo;Company&rdquo;), a biotechnology company developing breakthrough immunomodulation
therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the
withdrawal of the proposed public offering of common shares due to market conditions.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release shall not constitute an offer to sell or the solicitation
of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Tiziana Life Sciences</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tiziana Life Sciences is a clinical-stage biopharmaceutical company
developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana&rsquo;s
innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous
(IV) delivery. Tiziana&rsquo;s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical
development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana&rsquo;s technology
for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline
applications.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more information about Tiziana Life Sciences and its innovative
pipeline of therapies, please visit www.tizianalifesciences.com.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Foralumab</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological
drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary
Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328)
with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently
being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active
secondary progressive multiple sclerosis (NCT06292923).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb)
currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory
and neurodegenerative human diseases.<SUP>[1],[2]</SUP></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain statements made in this announcement are forward-looking statements.
These forward-looking statements are not historical facts but rather are based on the Company&rsquo;s current expectations, estimates, and projections
about its industry, its beliefs, and assumptions. Words such as &lsquo;anticipates,&rsquo; &lsquo;expects,&rsquo; &lsquo;intends,&rsquo; &lsquo;plans,&rsquo; &lsquo;believes,&rsquo; &rsquo;seeks,&rsquo; &lsquo;estimates,&rsquo;
and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance
and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company&rsquo;s control, are difficult
to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements.
The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements,
which reflect the view of the Company only as of the date of this announcement. Actual results may differ materially from those indicated
by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions
and other factors described more fully in the section entitled &lsquo;Risk Factors&rsquo; in Tiziana&rsquo;s Annual Report on Form 20-F
for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. The forward-looking
statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake
any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated
events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For further inquiries:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Tiziana Life Sciences Ltd</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Paul Spencer, Business Development, and Investor Relations<BR>
+44 (0) 207 495 2379<BR>
email:&nbsp;info@tizianalifesciences.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>[1]</SUP></TD><TD STYLE="text-align: justify">https://www.pnas.org/doi/10.1073/pnas.2220272120</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>[2]</SUP></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">https://www.pnas.org/doi/10.1073/pnas.2309221120</FONT></TD>
</TR></TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  V .P# 2(  A$! Q$!_\0
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MCZ?X<TWR+95BC4;I)7(!8^K&L*KC'3J=^#]K6]YW42;1[&XT[38K>ZOYKZX
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M>S8_\=K(ZCT;5_\ D"W_ /U[R?\ H)KP/]FK_D*:]_UQB_\ 0C7ONK G1KX
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ML2058>IKI_\ AI/0_P#H!7__ '\2@# U[PG\8?[ OVU76H;BP2!WGB:X5MR
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)XD$G%%% '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
